ESC Premium Access

Enthusiasm vs. evidence for COVID-19 pharmacotherapies: what do we know and what have we learnt?

Event: ESC Congress 2021 - The Digital Experience
Topic: Cardiovascular Disease in Special Populations
Session type: Official Joint Session
Date: 29 August 2021
Time: 10:30 - 11:15

Congress Session

Become an ESC member to access this resource

Become a member

Already a member? Sign in

5 presentations in this session

Prevention of thromboembolism in COVID-19.

Speaker: Associate Professor A. Martinez-Rubio (Sabadell, ES)
Thumbnail

COVID-19 myocarditis and myocardial injury: active participant or innocent bystander?

Speaker: Professor G. Dan (Bucharest, RO)
Thumbnail

Anti-inflammatory treatment of COVID-19 patients: which drugs and which patients?

Speaker: Doctor A. Semb (Oslo, NO)
Thumbnail

Enthusiasm vs. evidence for COVID-19 pharmacotherapies: what do we know and what have we learnt? – discussion.

Thumbnail

Enthusiasm vs. evidence for COVID-19 pharmacotherapies: what do we know and what have we learnt? - Chat Moderator.

Thumbnail

3 speakers from this session

Associate Professor Antonio Martinez-Rubio

University Hospital of Sabadell (Univ. Autonoma of Barcelona), Sabadell (Spain)
3 presentations
0 follower

Professor Gheorghe Andrei Dan

University of Medicine and Pharmacy Carol Davila, Bucharest (Romania)
12 presentations
3 followers

Doctor Anne Grete Semb

Diakonhjemmet Hospital, Oslo (Norway)
5 presentations
1 follower

Related content

ESC Premium Access

Update on endocarditis in 2021

3 December 2021

ESC Premium Access

Pregnancy in women with cardiovascular disease

3 December 2021

ESC Premium Access

Opening session

2 December 2021

This platform is supported by

logo Novo Nordisk